Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth's Q4 Revenues Climb 48 Percent

NEW YORK (GenomeWeb News) – MDxHealth today reported that its fourth-quarter 2011 revenues increased 48 percent year over year, driven by its pharmaco diagnostic business.

The Liege, Belgium-based firm reported Q4 revenues of €900,000 versus €600,000.

"The growth in revenues from our pharmaco diagnostic business in Q4 2011 of nearly 50 percent versus Q4 2010 represents continued validation and acceptance of our epigenetic technology and tests within the pharmaceutical industry," said MDxHealth CEO Jan Groen said in a statement. "Additionally, we made important strides in the development and validation of our ConfirmMDx for Prostate Cancer test and significantly advanced preparations for product launch in the coming months."

MDxHealth didn't provide its net earnings/loss for the quarter.

The firm reported full-year 2011 revenues of €2.7 million, up 8 percent from €2.5 million. Its full-year net loss declined to €6.9 million, or €.37 per share, from €8.3 million, or €.63 per share.

It trimmed its operating expenses for the year to €9.5 million from €10.5 million. The decline was due to a restructuring effort begun in 2010.

The molecular and companion diagnostics company finished the year with €11.1 million in cash and cash equivalents.

Two months ago, MDxHealth received CLIA certification for its lab in Irvine, Calif. Today, it said that it is currently building the sales and marketing infrastructure to support the launch of its ConfirmMDx for Prostate Cancer test in the US during the first half of this year.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more